2 weeks Ago By ABMN Staff
Envestnet Asset Management Inc. increased its holdings in shares of Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 36.9% in the 4th quarter, according to its most recent filing with the SEC.
The fund owned 90,742 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,443 shares during the period. Envestnet Asset Management Inc. owned approximately 0.
15% of Jazz Pharmaceuticals worth $11,175,000 at the end of the most recent reporting period. Other hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000.
CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $28,000. Allianz SE acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth $29,000. Jones Financial Companies Lllp increased its holdings in shares of Jazz Pharmaceuticals by 75.
1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the period. Finally, UMB Bank n.
a. raised its position in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter.
UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the last quarter.
Institutional investors own 89.14% of the company’s stock. Jazz Pharmaceuticals Stock Performance JAZZ stock opened at $102.
78 on Friday. The company has a 50 day moving average price of $128.14 and a 200 day moving average price of $122.
36. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.
06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.
26 and a quick ratio of 3.74. The stock has a market capitalization of $6.
24 billion, a PE ratio of 14.48, a price-to-earnings-growth ratio of 1.04 and a beta of 0.
42. Analyst Ratings Changes Get Our Latest Stock Report on Jazz Pharmaceuticals Insider Transactions at Jazz Pharmaceuticals In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, April 1st.
The stock was sold at an average price of $123.75, for a total value of $185,625.00.
Following the completion of the sale, the chief executive officer now directly owns 440,307 shares in the company, valued at $54,487,991.25. This trade represents a 0.
34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction dated Friday, March 7th.
The shares were sold at an average price of $138.60, for a total transaction of $981,288.00.
Following the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.
95 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 28,736 shares of company stock worth $4,023,305 over the last 90 days.
4.20% of the stock is owned by insiders. About Jazz Pharmaceuticals ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Featured Articles Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
